Pharmacokinetics and Pharmacodynamics of Gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a Granulocyte-Rich Exudate-Reference-Cited by-同舟云学术

Pharmacokinetics and Pharmacodynamics of Gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a Granulocyte-Rich Exudate

Published:2002-11 Issue:11 Volume:46 Page:3630-3633
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Trampuz Andrej¹,Laifer Gerd¹,Wenk Markus²,Rajacic Zarko¹,Zimmerli Werner³

Affiliation:

1. Division of Infectious Diseases

2. Division of Clinical Pharmacology, Departments of Internal Medicine and Research, University Hospitals, Basel

3. University Medical Clinic, Liestal, Switzerland

Abstract

ABSTRACT The pharmacokinetics of gatifloxacin were assessed in serum and in skin blister fluid (SBF), as was the pharmacodynamic activity in SBF. Five hours after a single dose of gatifloxacin, SBF killed 2.5 logs of Streptococcus pneumoniae and 1.5 log of Staphylococcus aureus during a 2-h incubation ex vivo.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.46.11.3630-3633.2002

Reference22 articles.

1. Blondeau, J. M. 1999. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J. Antimicrob. Chemother.43(Suppl. B):1-11.

2. Catchpole, C., J. M. Andrews, J. Woodcock, and R. Wise. 1994. The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg p.o. J. Antimicrob. Chemother.33:103-110.

3. State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men

4. Gajjar, D. A., F. P. LaCreta, H. D. Uderman, G. D. Kollia, G. Duncan, M. J. Birkhofer, and D. M. Grasela. 2000. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy20:49S-58S.

5. Grasela, D. M. 2000. Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin. Infect. Dis.31(Suppl. 2):S51-S58.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioactive thermoresponsive polyblend nanofiber formulations for wound healing;Materials Science and Engineering: C;2015-03

2. Gatifloxacin;Profiles of Drug Substances, Excipients and Related Methodology;2012

3. Development and Validation of an Ion-Pairing RP-HPLC Method for the Estimation of Gatifloxacin in Bulk and Formulations;Journal of Chromatographic Science;2007-04-01

4. Skin and skin structure infections: treatment with newer generation fluoroquinolones;Therapeutics and Clinical Risk Management;2007-04

5. Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials;World Journal of Gastroenterology;2007